These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18154114)

  • 1. [Immunohistochemical assay of cellular cycle markers: an alternative to chip-diagnosis of breast cancer].
    Petrov SV; Orlova RV; Raskin GA; Khacanov RSh
    Vopr Onkol; 2007; 53(5):526-30. PubMed ID: 18154114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer.
    Manna Edel F; Teixeira LC; Alvarenga M
    Tumori; 2006; 92(3):222-9. PubMed ID: 16869240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
    Gómez HL; Pinto JA; Olivera M; Vidaurre T; Doimi FD; Vigil CE; Velarde RG; Abugattas JE; Alarcón E; Vallejos CS
    Breast; 2011 Feb; 20(1):39-45. PubMed ID: 20705464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
    Abadjian G; Antoun R
    J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].
    Larsimont D; Durbecq V; Awada A; Di Leo A
    Bull Cancer; 2008 Mar; 95(3):344-51. PubMed ID: 18390415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
    Jiang L; Zhang X; Xiang C; Geradts J; Wei Q; Liang Y; Huang H; Xu JF
    Histol Histopathol; 2018 Aug; 33(8):835-842. PubMed ID: 29489009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.
    Sosińska-Mielcarek K; Duchnowska R; Winczura P; Badzio A; Majewska H; Lakomy J; Pęksa R; Pieczyńska B; Radecka B; Dębska S; Biernat W; Jassem J
    Breast; 2013 Dec; 22(6):1178-83. PubMed ID: 24060578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of e-cadherin in high-risk breast cancer.
    Howard EM; Lau SK; Lyles RH; Birdsong GG; Umbreit JN; Kochhar R
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):14-8. PubMed ID: 15459769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
    Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
    Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of malignancy of squamous cell lung cancer by clinico-morphological, immunohistochemical and prognostic study of tumor markers].
    Shvets SI; Kogan EA; Kovalenko VL; Soboleva IuV
    Vopr Onkol; 2009; 55(6):746-50. PubMed ID: 20210019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue.
    Su P; Zhang Q; Yang Q
    Diagn Pathol; 2010 Jun; 5():38. PubMed ID: 20565850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients.
    Fritz P; Tuczek HV; Offinger B; Schwarzmann P; Schieszl S; Wu X; Kleine B; Blödorn J; Multhaupt H
    Prog Histochem Cytochem; 1992; 26(1-4):146-58. PubMed ID: 1283015
    [No Abstract]   [Full Text] [Related]  

  • 19. [Auto-analysis of immunohistochemical findings for breast cancer using specified software and virtual microscopy].
    Tanaka M; Kuraoka K; Sakane J; Kodama Y; Nishimura T; Tanaka M; Tatsushima J; Saitou A; Taniyama K
    Rinsho Byori; 2012 Mar; 60(3):206-11. PubMed ID: 22568082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.